CareDx broadens HeartCare availability
September 17 2018 - 8:00AM
CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company
focused on the discovery, development, and commercialization of
clinically differentiated, high-value diagnostic solutions for
transplant patients, today announced the launch of the Surveillance
HeartCare® Outcomes Registry (SHORE).
CareDx will launch SHORE during the 22nd Annual Scientific
Meeting of the Heart Failure Society of America (HFSA), September
15-18, 2018 in Nashville, TN. SHORE is a prospective, multi-center,
observational, registry of patients receiving HeartCare
surveillance. HeartCare provides information about heart transplant
recipient immune activity and donor graft injury, including both
AlloMap® (gene expression profiling) and AlloSure-Heart®
(donor-derived cell-free DNA analysis).
“The marriage of gene expression profiling and dd-cfDNA promises
additional insights as we continuously strive to improve the
long-term care of our heart transplant patients,” says Shelley
Hall, MD, FACC, FHFSA, FAST, Chief, Transplant Cardiology, MCS and
Advanced Heart Failure at Baylor University Medical Center.
“HeartCare provides a comprehensive view into the health of the
heart allograft, so we are seeing strong initial interest from
transplant cardiologists to join SHORE,” said Jim Yee, MD, PhD,
Chief Medical Officer, CareDx. “The design of SHORE is derived from
the great experience with our previous OAR and D-OAR registries in
heart transplantation which included 35 centers more than 2200
patients.”
HeartCare establishes a standardized routine surveillance
schedule for heart transplant patients, and is broadly available
today to centers across the United States.
About CareDx CareDx,
Inc., headquartered in Brisbane, California, is a molecular
diagnostics company focused on the discovery, development and
commercialization of clinically differentiated, high-value
diagnostic solutions for transplant recipients. CareDx offers
products across the transplant testing continuum, including
AlloMap® and AlloSure™ for post-transplant surveillance and Olerup
SSP®, Olerup QTYPE®, and Olerup SBT™ for pre-transplant HLA
testing.
For more information, please visit: www.CareDx.com.
Forward Looking Statements
This press release contains forward-looking statements about our
business, research, development and commercialization efforts,
including statements regarding HeartCare and its potential
benefits. These forward-looking statements are based upon
information that is currently available to us and our current
expectations, speak only as of the date hereof, and are subject to
numerous risks and uncertainties, including risks associated with
successful research, development and planned commercialization of
our technologies, that are described in our filings with the SEC,
including the Annual Report on Form 10-K for the fiscal year ended
December 31, 2017 filed by us with the SEC on March 22, 2018 and
the periodic reports that we have subsequently filed with the
SEC. Any of these may cause our actual results, performance
or achievements to differ materially and adversely from those
anticipated or implied by our forward-looking statements. We
expressly disclaim any obligation, except as required by law, or
undertaking to update or revise any such forward-looking
statements.
CONTACTS:
CareDx, Inc.Sasha KingChief Commercial
Officer415-287-2393sking@caredx.com
Investor RelationsDavid ClairIntegrated Corporate Relations,
Inc.646-277-1266david.clair@icrinc.com
CareDx (NASDAQ:CDNA)
Historical Stock Chart
From Mar 2024 to Apr 2024
CareDx (NASDAQ:CDNA)
Historical Stock Chart
From Apr 2023 to Apr 2024